The therapeutic modality was primarily determined by agreement of at least two expert hepatologists. If patients were candidates for surgical resection, surgeons evaluated resectability, and the indocyanine green clearance test was performed to evaluate hepatic function. If the patients met the Milan criteria, liver transplantation was considered as an initial therapy for hepatocellular carcinoma (HCC).
1 Local ablative therapy including radio frequency ablation and percutaneous ethanol injection was performed depending on the number and size of tumors and their visibility and accessibility. Patients for whom curative modalities were not indicated were treated with transarterial chemoembolization upon consideration of their general condition and the absence of metastasis. Systemic therapy including sorafenib and systemic chemotherapy was considered if the tumor invaded the main portal vein or inferior vena cava or metastasized to distant organs. If patients were unable to tolerate active treatments, best supportive care was performed. After initial therapy, every patient underwent follow-up that included measurement of α-fetoprotein and protein induced by vitamin K absence or antagonist-II (PIVKA-II), as well as computed tomography scan to evaluate recurrence or progression of HCC. If HCC recurred or progressed, the treating physician determined the next treatment depending on patient condition and tumor status.
BCLC and HKLC staging
Each patient was classified according to both the Barcelona Clinic Liver Cancer (BCLC) and Hong Kong Liver Cancer (HKLC) staging systems. 2, 3 In the BCLC staging system, stage was determined based on Eastern Cooperative Oncology Group performance status, Child-Pugh class, tumor size, number of tumors, portal vein invasion, and metastasis. With this system, all patients were classified into five stages, including stage 0, A, B, C, and D. In the HKLC system, the main stages consisted of five stages from stage I to stage V. With the exception of stage I, the other stages included two substages, so that a total of nine stages existed in HKLC staging system. All HCC patients were classified with these systems based on performance status, Child-Pugh score, tumor status, and status of extrahepatic vascular invasion. All patients were then arranged according to their BCLC stage, HKLC stage, and the initial treatment modality they received. After staging, we classified patients into three groups and compared their survival outcomes; one group followed both the BCLC and HKLC staging systems, another group followed only the BCLC staging system, and the other group followed only the HKLC staging system. 
